Guardant Health, Inc. (GH) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$160.65

From 52W high−15.67%

Volume1.87M

Market cap$21.19B

P/E (TTM)—

P/S (TTM)17.9x

Div yield—

Key dataOct 19, 2026

Open

$160.65

From 52W high

−15.67%

Volume

1.87M

Market cap

$21.19B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−53.1x

P/E (TTM)

—

RSI (14)

40.6

MomentumView details →

1D Return

−0.45%

YTD Return

+56.04%

SummaryUpdated Jun 1, 2026

Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company founded in 2011 and headquartered in Redwood City, California. The company went public in October 2018 and has established itself as a leader in liquid biopsy technology, which uses blood tests to detect and analyze cancer-related genetic material. Guardant Health operates primarily in the United States with expanding international presence, serving oncologists, patients, and biopharmaceutical companies with innovative blood-based cancer testing solutions.

Ask drillr about Guardant Health, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−53.1x

EV/Sales

18.5x

P/S (TTM)

17.9x

P/B (TTM)

−95.1x

ProfitabilityView details →

Gross Margin

65.01%

Net Margin

−38.33%

EBITDA Margin

−34.76%

ROE (TTM)

203.46%

ROA (TTM)

−23.71%

Asset Turnover

0.62x

GrowthView details →

Revenue YoY

+42.74%

EPS YoY

−4.18%

FCF YoY

+11.41%

Revenue CAGR 3Y

+29.75%

EPS CAGR 3Y

+6.74%

EBITDA YoY

−11.63%

MomentumView details →

1D Return

−0.45%

YTD Return

+56.04%

1Y Return

+127.04%

RSI (14)

40.6

vs 50D SMA

−5.07%

vs 200D SMA

+24.96%

Capital & dividendView details →

Debt/Equity

−7.61x

Current Ratio

4.03x

Quick Ratio

3.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.90

EPS Surprise

−18.14%

Beats (12Q)

7/12

Next Q EPS Est

−$0.74

Avg Surprise (4Q)

−24.82%

Rev Surprise

6.60%

Financials snapshotView financials →

Revenue (TTM)

1.18B

Net Income (TTM)

−453.44M

Op. CF (TTM)

−185.19M

Next earningsNov 5, 2026 →

Latest newsMore news →

Guardant Health announced that it will report its third-quarter 2026 financial results after market close on November 5, 2026.11d ago

Guardant Health announced that Cancer Research Communications published results from the COSMOS-MEL01 study, the first prospective multicenter evaluation of its tissue-free epigenomic Guardant Reveal blood test for molecular residual disease detection and recurrence monitoring in melanoma patients.14d ago

Similar companies

Joinn Laboratories(China)Co.,Ltd.06127.HK Exact Sciences CorporationEXAS 安图生物603658.SH Quest Diagnostics IncorporatedDGX Medpace Holdings, Inc.MEDP Revvity, Inc.RVTY Find similar companies →

Latest newsMore news →

Guardant Health announced that it will report its third-quarter 2026 financial results after market close on November 5, 2026.11d ago Guardant Health announced that Cancer Research Communications published results from the COSMOS-MEL01 study, the first prospective multicenter evaluation of its tissue-free epigenomic Guardant Reveal blood test for molecular residual disease detection and recurrence monitoring in melanoma patients.14d ago